Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-31
2005-05-31
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S176000, C514S182000, C540S110000, C540S114000, C540S120000, C552S550000, C552S551000, C552S552000
Reexamination Certificate
active
06900192
ABSTRACT:
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5541348 (1996-07-01), Arya et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6103932 (2000-08-01), Horwell et al.
patent: 6117906 (2000-09-01), Silverman et al.
patent: 0 272 462 (1988-06-01), None
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31074 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/15611 (2000-03-01), None
patent: WO 00/23067 (2000-04-01), None
patent: WO 00/31020 (2000-06-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 01/20331 (2001-03-01), None
Ballatore et al., “Synthesis and Spectroscopic Analysis of Modified Bile Salts.” Steroids, vol. 41(2), pp. 197-206, 1983.*
Nair et al., “Electron Impact Ionization Mass Spectra of Lithocholyl Amides: Evidences for a C(20) to C(23) Rearrangement Involving the Loss of a C4H9 Fragment.” Organic Mass Spectrometry, vol. 29(7), pp. 335-341, 1994.*
Swann et al., “Use of the Intestinal and Hepatic Bile Acid Transporters for Drug Delivery.”, Adv. Drug Delivery Rev., vol. 20, pp. 59-82, 1996.*
Batta, A.K., et al. “Characterization of Sarcosylsarcouradeoxycholic Acid Formed During the Synthesis of Sarcoursodeoxycholic Acid.”J. Lipid Research. 30: 771-774 (1989).
Huijghebaert, S.M., et al. “Pancreatic Carboxypeptidase Hydrolysis of Bile Acid-Amino Acid Conjugates: Selective Resistance of Glycine and Taurine Amidates.”Gastroenterology. 90: 306-315 (1986).
Adibi, S.A.,Gastroenterology, 1997, 113, pp. 332-340.
Baringhaus, K.H., et al.,Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/ bile acid cotransporter, J. Lipid Res., 1999, 40, pp. 2158-2168.
Bryans, J. S., et al.,3-Substituted GABA analogs with central nervous system activity: a review, Med. Res. Rev., 1999, 19, pp. 149-177.
Bundgaard, H., inDesign of Prodrugs(Bundgaard, H. Ed.), Elsevier Science B.V., 1985, pp. 1-92.
Dieck, S.T., et al.,GLIA, 1999, 25, pp. 10-20.
Ho, N. F. H.,Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption, Ann. N. Y. Acad. Sci., 1987, 507, pp. 315-329.
Jezyk, N., et al.,Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers, Pharm. Res., 1999, 16, pp. 519-526.
Kagedahl, M., et al.,Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity, Pharm. Res., 1997, 14, pp. 176-180.
Kim, D.C.,Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides, J. Drug Targeting, 1993, 1, pp. 347-359.
Kramer, W, et al.,Liver-specific drug targeting by coupling to bile acids, J. Biol. Chem.,/1992, 267, pp. 18598-18604.
Kramer, W., et al.,Intestinal absorption of peptides by coupling to bile acids,J. Biol. Chem., 1994a, 269, pp. 10621-10627.
Kramer, W.,Bile acid derived HMG-CoA reductase inhibitors, Biochim. Biophys. Acta., 1994b, 1227, pp. 137-154.
Kramer, W., et al.,Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters, J. Lipid Res., 1999, 40, pp. 1604-1617.
Kullak-Ublick, G.A., et al.,Hepatobiliary transport, J. Hepatology,2000, 32 (Suppl. 1), pp. 3-18.
Leibach, et al.,Ann. Rev. Nutr., 1996, 16, pp. 99-119.
Mills, C.O., et al.,Ileal absorption of tyrosine-conjugated bile acids in Wistar rats,Biochim. Biophys. Acta, 1987, 926, pp. 154-159.
Navia, M.A,Design principles for orally bioavailable drugs, Drug Discovery Today, 1996, 1, pp. 179-189.
Petzinger, E., et al.,Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids, Hepatology, 1995, 22, pp. 1801-1811.
Swaan, P.W.,Use of the intestinal and hepatic bile acid transporters for drug delivery, Adv. Drug Delivery Rev, 1996, 20, pp. 59-82.
Swaan, P.W., et al.,Enhanced transepithelial transport of peptides by conjugation to cholic acid, Bioconj. Chem, 1997, 8, pp. 520-525.
Tsuji, A., et al.,Carrier-mediated intestinal transport of drugs, Pharm. Res., 1996, 13, pp. 963-977.
Wong, et al.,Am. J. Physiol., 1998, 275, pp. C967-C975.
Cundy Kenneth C.
Gallop Mark A.
Zhou Cindy X.
Badio Barbara P.
Burns Doane Swecker & Mathis L.L.P.
XenoPort, Inc.
LandOfFree
Bile-acid conjugates for providing sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid conjugates for providing sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid conjugates for providing sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453021